A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) - CVAY736F12301

ovartis Pharma AG0 个研究点目标入组 338 人开始时间: 2024年7月8日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: ovartis Pharma AG
入组人数: 338

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 0 至 65+（—）
性别: All

入选标准

•Male and Female participants aged 12 years or older at the time of screening, or limited to 18 years or older in European Economic Area countries and other countries where inclusion of participants below 18 years is not allowed, Diagnosis of systemic lupus erythematosus meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) SLE classification criteria at least 6 months prior to screening, Elevated serum titers at screening of Antinuclear Antibodies (=1:80) as determined by a central laboratory with a SLE typical fluorescence pattern., Currently receiving corticosteroids and/or anti-malarial treatment and/or another Disease-modifying antirheumatic drug (DMARD) as specified in the protocol., SLEDAI-2K Criteria at screening: SLEDAI-2K score =6 points, excluding points attributed to fever, lupus headache, alopecia, and organic brain syndrome; British Isles Lupus Assessment Group-2004 disease activity level at screening of at least 1 of the following: British Isles Lupus Assessment Group-2004 level A disease in =1 organ system, Or British Isles Lupus Assessment Group-2004 level B disease in =2 organ systems, Weigh at least 35 kg at screening

排除标准

•Prior treatment with ianalumab, Evidence of active tuberculosis infection, History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV) test result at screening, Any one of the following laboratory values prior to randomization: Platelets <25000/mm^3 (<25 x 10^3/µL) Hemoglobin (Hgb) <8.0 g/dL (<5 mmol/L), or <7.0 g/dL (<4.3 mmol/L) if related to participant's SLE such as in active hemolytic anemia Absolute neutrophil count (ANC) (<0.8 x 10^3/ µL), Severe organ dysfunction or life-threatening disease at screening, Presence of severe lupus kidney disease as defined by proteinuria above 2g/day or equivalent using spot urine protein creatinine ratio, US (and other countries, if locally required): sexually active males unless using barrier protection during intercourse while taking study treatment, Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while on study treatment and for 6 months after stopping of investigational drug., Any surgical, medical, psychiatric or additional physical condition that may jeopardize participation in this study, Receipt of live/attenuated vaccine within a 4-week period before first dosing, Any uncontrolled, co-existing serious disease, which in the opinion of the investigator will place the participant at risk for participation or interfere with evaluation for SLE-related symptoms, Non-lupus conditions such as asthma, gout or urticaria, requiring intermittent or chronic treatment with systemic CS, History of malignancy of any organ system other than localized basal cell carcinoma of the skin or in situ cervical cancer, Pregnant or nursing (lactating) women., History of receiving following treatment I) high dose corticosteroids, calcineurin inhibitors, JAK or other kinase inhibitors or other DMARD (except as listed in inclusion criteria) 12 weeks prior to screening II) Cyclophosphamide or biologics such as immunoglobulins (i.v. or s.c.), plasmapheresis, anti-type I interferon receptor biologic agents, anti- CD40 agents, CTLA4-Fc Ig or B-cell activating factor-targeting agents administered within 24 weeks prior to screening; belimumab administered within 12 weeks prior to screening. III) Any B-cell depleting therapies, other than ianalumab administered within 36 weeks prior to randomization or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower) IV) Traditional Chinese medicines administered within 30 days prior to randomization, Active viral, bacterial or other infections requiring intravenous or intramuscular treatment for clinically significant infection, Chronic infection with hepatitis B (HBV) or hepatitis C (HCV)

研究者

发起方

ovartis Pharma AG

相似试验

进行中（未招募）

不适用

EUCTR2007-001451-19-GRAstellas Pharma Europe B.V.2,160

进行中（未招募）

不适用

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder - SCORPIOSymptoms of Overactive BladderMedDRA version: 9.1Level: LLTClassification code 10059617Term: Overactive bladder

EUCTR2007-001451-19-LTAstellas Pharma Europe B.V.2,160

进行中（未招募）

不适用

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder. - SCORPIOSymptoms ofOveractive BladderMedDRA version: 14.1Level: HLGTClassification code 10004994Term: Bladder and bladder neck disorders (excl calculi)System Organ Class: 10038359 - Renal and urinary disorders

EUCTR2007-001451-19-ITAstellas Pharma Europe B.V.2,160

进行中（未招募）

不适用

EUCTR2007-001451-19-PTAstellas Pharma Europe B.V.2,160

进行中（未招募）

不适用

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-Centre Dose Ranging Study with the Beta-3 AGONist YM178 in Patients with Symptomatic Overactive Bladder (DRAGON) - DRAGOOveractive bladder

EUCTR2005-002256-17-BEAstellas Pharma Europe B.V.1,040